Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.
Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to “continued strategic progress” and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management
This problem has a solution, and Pfizer is implementing it.
BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings.
The stock's 6.4% yield is attractive, but it comes with risk.
Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.
Novavax secures key partnerships and raises 2026 outlook while advancing its adjuvant platform in infectious disease and oncology.
Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?
Pfizer (PFE) is back in focus after its second quarter 2026 update, which paired a reported net loss and sizeable non cash impairments with higher full year revenue guidance and solid non COVID product performance. See our latest analysis for Pfizer. The latest results and raised revenue guidance have lifted sentiment toward Pfizer, with the stock showing a 1 month share price return of 8.81% and a 1 year total shareholder return of 15.42%, although longer term total shareholder returns...
Pfizer increased its savings target and revenue outlook, but investors remained focused on patent expirations and pipeline execution.
PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.
Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% o
Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
Moby summary of Pfizer Inc.'s Q2 2026 earnings call
The quarter exposed where Pfizer's recovery is really coming from
Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported...
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer faces $17 billion patent cliff as investors brace for earnings
Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
The drugmaker posted adjusted earnings of 77 cents per share and now expects full-year revenue of $60.5 billion to $62.5 billion
Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect.
Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
